Equities researchers at Oppenheimer started coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) in a research note issued on Tuesday, MarketBeat reports. The brokerage set an “outperform” rating and a $104.00 price target on the stock. Oppenheimer’s price objective indicates a potential upside of 168.66% from the stock’s current price.
A number of other analysts have also commented on MLTX. The Goldman Sachs Group began coverage on MoonLake Immunotherapeutics in a research note on Tuesday, April 2nd. They set a “neutral” rating and a $62.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 11th. William Blair reaffirmed an “outperform” rating and set a $92.00 price target on shares of MoonLake Immunotherapeutics in a research note on Monday, February 26th. Wedbush reissued an “outperform” rating and issued a $92.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Wednesday, March 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, June 10th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $76.57.
Read Our Latest Stock Analysis on MLTX
MoonLake Immunotherapeutics Trading Up 0.7 %
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last posted its earnings results on Sunday, May 12th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, equities research analysts forecast that MoonLake Immunotherapeutics will post -1.23 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. Quarry LP bought a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $51,000. Barclays PLC bought a new stake in MoonLake Immunotherapeutics during the 3rd quarter valued at $189,000. Stratos Wealth Partners LTD. acquired a new position in MoonLake Immunotherapeutics during the fourth quarter worth $202,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter valued at $217,000. Finally, Bellevue Group AG acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter valued at about $221,000. Institutional investors and hedge funds own 93.85% of the company’s stock.
MoonLake Immunotherapeutics Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
- Five stocks we like better than MoonLake Immunotherapeutics
- What is the Australian Securities Exchange (ASX)
- Tesla Stock: The Pay Package Battle and Its Impact on Investors
- Profitably Trade Stocks at 52-Week Highs
- Call Option Interest Soars in These 3 Stocks
- What is the Euro STOXX 50 Index?
- Top 3 Dividend Stocks Trading Close to 52-Week Low Prices
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.